BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27919978)

  • 1. Control of Nausea and Vomiting in Patients with Colorectal Cancer Receiving Chemotherapy with Moderate Emetic Risk.
    Suzuki A; Kobayashi R; Fujii H; Iihara H; Takahashi T; Yoshida K; Itoh Y
    Anticancer Res; 2016 Dec; 36(12):6527-6533. PubMed ID: 27919978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
    Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
    BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan.
    Tsuji Y; Baba H; Takeda K; Kobayashi M; Oki E; Gotoh M; Yoshida K; Shimokawa M; Kakeji Y; Aiba K
    Expert Opin Pharmacother; 2017 Jun; 18(8):753-758. PubMed ID: 28395603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea.
    Takemoto H; Nishimura J; Komori T; Kim HM; Ota H; Suzuki R; Ikenaga M; Ikeda M; Yamamoto H; Satoh T; Hata T; Takemasa I; Mizushima T; Doki Y; Mori M;
    Int J Clin Oncol; 2017 Feb; 22(1):88-95. PubMed ID: 27465476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of adherence to guidelines for antiemetic medication enhances emetic control in patients with colorectal cancer receiving chemotherapy of moderate emetic risk.
    Fujii H; Iihara H; Ishihara M; Takahashi T; Yoshida K; Itoh Y
    Anticancer Res; 2013 Dec; 33(12):5549-56. PubMed ID: 24324096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
    Nawa-Nishigaki M; Kobayashi R; Suzuki A; Hirose C; Matsuoka R; Mori R; Futamura M; Sugiyama T; Yoshida K; Itoh Y
    Anticancer Res; 2018 Feb; 38(2):877-884. PubMed ID: 29374715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation.
    Stinson J; Chan K; Lee J; Chow R; Cheon P; Giotis A; Pasetka M; Wan BA; Chow E; DeAngelis C
    Ann Palliat Med; 2017 Aug; 6(Suppl 1):S13-S20. PubMed ID: 28595433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens.
    Iihara H; Ishihara M; Fujii H; Yoshimi C; Yamada M; Suzuki A; Yamaguchi K; Futamura M; Yoshida K; Itoh Y
    J Cancer; 2016; 7(5):569-75. PubMed ID: 27053955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
    Koch S; Wein A; Siebler J; Boxberger F; Neurath MF; Harich HD; Hohenberger W; Dörje F
    Support Care Cancer; 2013 Sep; 21(9):2395-402. PubMed ID: 23568765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
    Craver C; Gayle J; Balu S; Buchner D
    J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
    Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G
    Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States.
    Schwartzberg L; Morrow G; Balu S; Craver C; Gayle J; Cox D
    Curr Med Res Opin; 2011 Aug; 27(8):1613-22. PubMed ID: 21696263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.
    Gilmore JW; Peacock NW; Gu A; Szabo S; Rammage M; Sharpe J; Haislip ST; Perry T; Boozan TL; Meador K; Cao X; Burke TA
    J Oncol Pract; 2014 Jan; 10(1):68-74. PubMed ID: 24065402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI study.
    Vanbockstael J; Coquan E; Gouerant S; Allouache D; Faveyrial A; Noal S; Delcambre C; Galais MP; Héron JF; Lefebvre AC; Sevin E; Hrab I; Polycarpe F; André M; Kaluzinski L; Gervais R; Gunzer K; Vié B; Saucier G; Lemenand N; Grellard JM; Clarisse B; Dugué AE; Joly F
    Support Care Cancer; 2016 Mar; 24(3):1131-8. PubMed ID: 26268784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and management of chemotherapy-induced nausea and vomiting.
    Moradian S; Howell D
    Int J Palliat Nurs; 2015 May; 21(5):216, 218-24. PubMed ID: 26107543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
    Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
    Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
    Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
    J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An assessment tool for chemotherapy-induced nausea and vomiting and intervention outcomes].
    Aimono Y; Suzuki S; Nemoto M; Saito Y; Aoyama Y; Joko F; Maruyama T; Kamoshida T
    Gan To Kagaku Ryoho; 2013 Dec; 40(13):2551-4. PubMed ID: 24335368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.